Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Scientech Research LLC

Scientech Research LLC lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 66.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,516 shares of the company’s stock after selling 2,958 shares during the period. Scientech Research LLC’s holdings in Neurocrine Biosciences were worth $209,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Lion Point Capital LP boosted its stake in Neurocrine Biosciences by 11.3% during the 2nd quarter. Lion Point Capital LP now owns 8,350 shares of the company’s stock valued at $1,150,000 after purchasing an additional 850 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Neurocrine Biosciences by 0.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,401 shares of the company’s stock worth $17,264,000 after buying an additional 1,074 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at approximately $982,000. Daymark Wealth Partners LLC raised its stake in Neurocrine Biosciences by 18.3% during the 2nd quarter. Daymark Wealth Partners LLC now owns 1,774 shares of the company’s stock valued at $244,000 after acquiring an additional 274 shares in the last quarter. Finally, APG Asset Management US Inc. boosted its position in Neurocrine Biosciences by 2.6% during the 2nd quarter. APG Asset Management US Inc. now owns 27,953 shares of the company’s stock worth $3,916,000 after acquiring an additional 721 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the transaction, the chief financial officer now directly owns 31,528 shares in the company, valued at $4,741,180.64. The disclosure for this sale can be found here. Insiders sold 61,798 shares of company stock valued at $9,274,196 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on NBIX shares. Royal Bank of Canada lowered their price target on Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating on the stock in a report on Thursday, August 29th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Thursday, August 29th. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $162.20.

Neurocrine Biosciences Trading Down 0.9 %

Shares of NASDAQ NBIX opened at $114.15 on Wednesday. The firm has a market capitalization of $11.49 billion, a PE ratio of 31.45 and a beta of 0.37. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98. The business has a 50-day moving average price of $134.89 and a two-hundred day moving average price of $137.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million for the quarter, compared to analysts’ expectations of $545.98 million. During the same period in the previous year, the firm posted $0.95 earnings per share. The business’s revenue for the quarter was up 30.4% on a year-over-year basis. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.